Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era

Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era

Target-oriented agents improve metastatic colorectal cancer (mCRC) survival in combination with chemotherapy. However, the majority of patients experience disease progression after first-line treatment and are eligible for second-line approaches. In such a context, antiangiogenic and anti-Epidermal...

Full description

Bibliographic Details
Main Authors: Guido Giordano, Pietro Parcesepe, Giuseppina Bruno, Annamaria Piscazzi, Vincenzo Lizzi, Andrea Remo, Massimo Pancione, Mario Rosario D’Andrea, Elena De Santis, Luigi Coppola, Michele Pietrafesa, Alberto Fersini, Antonio Ambrosi, Matteo Landriscina
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:International Journal of Molecular Sciences
Subjects:
colorectal cancer
second-line therapy
precision medicine
chemotherapy
anti-angiogenic treatment
anti-EGFR
Online Access:https://www.mdpi.com/1422-0067/22/14/7717

Internet

https://www.mdpi.com/1422-0067/22/14/7717

Similar Items